Drugs / PF-07209960
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04628780 | Dec 2020 → May 2023 | colorectal carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma, ovarian carcinoma +2 | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07209960 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04628780 ↗ |
| Modality | Protein / enzyme biologic | “an anti-PD-1 targeting IL-15 fusion protein” NCT04628780 ↗ |